Clinical Trial

To Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors

Completed
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to explore the quantitative relationship between in vivo exposure and efficacy, and the relationship between in vivo exposure and the risk of adverse reactions after adjuvant treatment of imatinib in patients with intermediate and high-risk GIST in the real world, so as to determine the optimal treatment window for imatinib .
Trial Details
NCT Number NCT07614841
Lead Sponsor First Affiliated Hospital, Sun Yat-Sen University
Conditions Gastrointestinal Stromal Tumors (GISTs)
Enrollment 328 participants
Start Date 2015-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29